Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?

Authors :: Maillart E
Lippi A
Lubetzki C
Louapre C
Papeix C
Source :: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2018 Feb; Vol. 20, pp. 220-222. Date of Electronic Publication: 2018 Feb 06.
Publication Year :: 2018
Abstract: Background: We report a dramatic clinical and radiological worsening within two months after rituximab initiation in a patient with NeuroMyelitis Optica/Multiple Sclerosis (NMO/MS) overlap syndrome.<br />Methods: Case study.<br />Results: A 45-year-old Caucasian woman with NMO/MS overlap syndrome experienced a severe myelitis nine weeks after first rituximab infusion, with extensive new gadolinium-enhanced spinal cord lesions.<br />Conclusion: This case report illustrates the limits of MS and NMO-Spectrum Disorder classification and challenges the criteria of therapeutic failure within the 6 months after rituximab initiation.<br /> (Copyright © 2018 Elsevier B.V. All rights reserved.)

Subjects :: Female
Humans
Middle Aged
Multiple Sclerosis classification
Multiple Sclerosis diagnostic imaging
Neuromyelitis Optica classification
Neuromyelitis Optica diagnostic imaging
Recurrence
Syndrome
Time Factors
Treatment Failure
Immunologic Factors therapeutic use
Multiple Sclerosis drug therapy
Neuromyelitis Optica drug therapy
Rituximab therapeutic use

Full Text Access

Tools